Goyang-si, South Korea

Inho Jo


Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2006

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Inho Jo: Innovator in Neurodegenerative Disorder Research

Introduction

Inho Jo is a prominent inventor based in Goyang-si, South Korea. He has made significant contributions to the field of neurodegenerative disorders through his innovative research and patented inventions. His work focuses on developing therapeutic agents that can potentially prevent and treat conditions such as Alzheimer's disease.

Latest Patents

Inho Jo holds a patent for a novel protein that inhibits the aggregation of beta amyloid peptide. This invention relates to a protein that effectively prevents the aggregation of beta amyloid, which is crucial in the development of Alzheimer's disease. The patent also includes a gene coding for the protein and a strain that produces it. The therapeutic agent derived from this protein can be utilized for the prevention and treatment of neurodegenerative disorders.

Career Highlights

Inho Jo is affiliated with the National Institute of Health, where he conducts his research. His work has garnered attention for its potential impact on treating neurodegenerative diseases. With a focus on innovative solutions, he continues to explore new avenues in medical research.

Collaborations

Inho Jo collaborates with notable colleagues, including Sangmee Ahn Jo and Ho Jeong Kwon. Their combined expertise enhances the research efforts aimed at addressing complex health issues related to neurodegenerative disorders.

Conclusion

Inho Jo's contributions to the field of neurodegenerative disorder research highlight the importance of innovation in medicine. His patented work on inhibiting beta amyloid aggregation represents a significant step forward in developing effective treatments for Alzheimer's disease.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…